Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Suzhou Ascentage to Start US Trial of Novel EED Protein Inhibitor

publication date: Jun 30, 2022

Suzhou Ascentage Pharma has been cleared to start US trials of its novel inhibitor of the embryonic ectoderm development (EED) protein, which will be tested in patients with solid tumors or hematologic malignancies. The EED protein can stimulate the methyltransferase activity of EZH2, which promotes the development and progression of tumors. According to Ascentage, APG-5918 is an orally active, potent, selective, small-molecule EED inhibitor with high binding affinity. By regulating tumor epigenetics and microenvironment, the company believes APG-5918 has the potential to overcome tumor resistance and deliver complete and durable tumor regression. More details....

Stock Symbol: (HK: 6855)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital